Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late. Health officials say it's important to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY Omicron XBB.1.5? COMIRNATY Omicron XBB.1.5 is a vaccine given to prevent coronavirus disease ...

Please report side effects. See the full CMI for further details. 1. Why am I being given COMIRNATY JN.1? COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19 ...